Advertisement

Search Results

Advertisement



Your search for The ,The matches 30461 pages

Showing 1 - 50


RUBY Trial in Endometrial Cancer and Breast Cancer Screening After Treatment

On this episode, we discuss two important studies presented over the past month at two oncology meetings, including the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer and the Miami Breast Cancer Conference.

hepatobiliary cancer
genomics/genetics

Hypercalcemia in Patients With Cholangiocarcinoma

In a study reported in a research letter in JAMA Oncology, Konstantinidou et al found that the prevalence of hypercalcemia increased over time in patients with cholangiocarcinoma and was significantly more common in those with IDH1-mutant intrahepatic disease. Study Details The study involved...

gynecologic cancers

Effect of Insurance Status on Racial and Ethnic Inequities in the Diagnosis of Advanced-Stage Cervical Cancer

In a study reported in JAMA Network Open, Holt et al found that health insurance status was a substantial mediator in the diagnosis of advanced-stage vs early-stage cervical cancer across ethnicity and race in patients from the United States. Study Details The retrospective, cross-sectional,...

breast cancer

Extended Performance of an Image-Based Short-Term Risk Model for Predicting Breast Cancer

In a Swedish case-cohort study reported in the Journal of Clinical Oncology, Eriksson et al found that an image-based short-term risk model outperformed a traditional lifestyle/familial risk–based risk model in predicting the likelihood of development of breast cancer over a 10-year period. Study...

skin cancer
immunotherapy

Nivolumab Injected Directly Into Spinal Fluid May Be Safe and Effective for Some Patients With Melanoma Who Have Leptomeningeal Disease

Researchers have found that a novel approach to administer intrathecal and intravenous nivolumab has proven safe and improved survival in a subset of patients who developed leptomeningeal disease from metastatic melanoma, according to a new study published by Glitza Olivia et al in Nature ...

skin cancer
genomics/genetics

Researchers Uncover How Incurable Skin Cancer May Resist Treatment at the End of Life

Researchers have revealed the potential mechanisms contributing to treatment resistance in patients with melanoma at the end of life, according to a new study published by Spain et al in Cancer Discovery. “These results present the most detailed picture yet of what melanoma looks like at the final...

gynecologic cancers

Clinical Trial Participation May Be Associated With Improved Overall Survival in Patients With Ovarian Cancer

Investigators have found that patients with platinum-resistant epithelial ovarian cancer who participate in clinical trials may have higher rates of overall survival compared with those who don’t participate in clinical trials, according to findings presented by Morton et al at the Society of...

bladder cancer
immunotherapy
genomics/genetics

How Do Novel Genetic Subtypes of Urothelial Carcinoma Respond to Immune Checkpoint Blockade?

In a study reported in the Journal of Clinical Oncology, Sarfaty et al identified novel genetic subtypes of urothelial carcinoma exhibiting different responses to immune checkpoint blockade. Study Details In the multicenter study, whole-exome sequencing was performed on tumor specimens from 88...

gynecologic cancers

Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer

Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented by Ackroyd et al and Adjei et al at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on ...

gynecologic cancers

Addition of Immunotherapy to Chemotherapy Regimen May Increase Progression-Free Survival in Patients With Advanced or Recurrent Endometrial Cancer

Adding immunotherapy to standard chemotherapy may result in significantly longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to the findings from two novel studies presented by Eskander et al and Mirza et al at the Society of Gynecologic Oncology...

gynecologic cancers

Addition of Gemcitabine to Cisplatin and Intensity-Modulated Radiation Therapy May Improve Outcomes for Patients With Locally Advanced Vulvar Cancer

Researchers have found that concurrent treatment with gemcitabine as well as cisplatin and intensity-modulated radiation therapy may effectively increase the pathologic complete response rates in patients with locally advanced squamous cell carcinoma of the vulva, according to findings presented by ...

issues in oncology

Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods

In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....

solid tumors
immunotherapy

FDA Grants Full Approval to Pembrolizumab for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors

On March 29, the U.S. Food and Drug Administration (FDA) granted full approval to the anti–PD-1 therapy pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, as...

gynecologic cancers

Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo

Researchers have found no significant differences in overall survival between patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib or placebo, according to new findings presented by Matulonis et...

gynecologic cancers

Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy

Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse events, and positive health outcomes in patients with ovarian cancer who have a germline...

gynecologic cancers

Atezolizumab May Be an Effective Primer for Chemoradiation in Patients With Locally Advanced Cervical Cancer

After comparing the efficacy of the anti–PD-L1 inhibitor atezolizumab prior to and concurrently with chemoradiation, researchers have indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with...

gynecologic cancers
immunotherapy

RUBY Trial: Dostarlimab Plus Carboplatin and Paclitaxel in Advanced Endometrial Cancer

Adding immunotherapy to standard chemotherapy for the first-line treatment of advanced or the first recurrence of endometrial cancer significantly improved progression-free survival compared to chemotherapy alone, according to data presented by Mansoor Raza Mirza, MD, and colleagues at the March...

pancreatic cancer

Antibiotic Use and Survival Among Patients With Metastatic Pancreatic Cancer Receiving Specific Chemotherapy Regimens

In a retrospective cohort study reported in JAMA Network Open, Fulop et al found that perichemotherapy use of antibiotics was associated with improved survival in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line gemcitabine-based chemotherapy, but not in those...

breast cancer

Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer

In a phase IIb trial reported in JAMA Oncology, Serrano et al found that exemestane at 25 mg three times weekly was noninferior to the standard dosing of 25 mg once daily in terms of serum estradiol reduction among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast...

supportive care
issues in oncology

Brown Adipose Tissue May Not Be Associated With Cancer Cachexia, May Not Worsen Cancer Mortality

Brown adipose tissue may not be associated with cachexia, according to an article published by Eljalby et al in the American Journal of Physiology Endocrinology and Metabolism. The findings also suggested that brown adipose tissue does not increase cancer mortality. Background Brown adipose tissue...

gynecologic cancers

Risk of Cervical Cancer May Be Twice as High in Patients With Mental Illnesses

Patients who have a mental illness, neuropsychiatric disability, or substance use disorder may be less likely to undergo gynecological smear tests and may have over twice the risk of developing cervical cancer, according to a new study published by Hu et al in The Lancet Public Health. The findings ...

breast cancer

New Prognostic Staging System for De Novo Metastatic Breast Cancer

In a study reported in the Journal of Clinical Oncology, Jennifer K. Plichta, MD, MS, and colleagues formulated a novel prognostic staging system for de novo metastatic breast cancer. Study Details The staging system was developed using data from 42,467 patients from the National Cancer Database...

breast cancer
geriatric oncology

Change in Frailty Status Among Older Patients Undergoing Locoregional Therapy for Early-Stage Breast Cancer

In a cohort study reported in a research letter in JAMA Surgery, Minami et al found that frailty status worsened in a sizable proportion of older patients receiving locoregional therapy—including lumpectomy or mastectomy—for early-stage breast cancer. Baseline robust status and mastectomy were...

skin cancer
genomics/genetics

Naporafenib Plus Trametinib in Advanced NRAS-Mutant Melanoma

As reported in the Journal of Clinical Oncology by de Braud et al, findings in the expansion cohort of a phase Ib trial indicate activity with the combination of the BRAF/CRAF kinase inhibitor naporafenib and trametinib in patients with advanced or metastatic NRAS-mutant melanoma. Study Details In ...

multiple myeloma

Significance of the MGUS-Like Phenotype in Patients With Multiple Myeloma and Light Chain Amyloidosis

In a study reported in the Journal of Clinical Oncology, Burgos et al developed an algorithm to identify patients with multiple myeloma and light-chain amyloidosis who have the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype, as well as identified the association of the...

colorectal cancer

Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy

In a study reported in JAMA Oncology, En Cheng, MD, PhD, of Kaiser Permanente Northern California, Jeffrey ­Meyerhardt, MD, MPH, FASCO, of Dana-Farber Cancer Institute, and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were...

gynecologic cancers

Smoking Cessation Intervention in Patients With a History of Cervical Intraepithelial Neoplasia or Cervical Cancer

In a study reported in the Journal of Clinical Oncology, Vidrine et al found that a smoking cessation intervention was not effective among patients with a history of cervical intraepithelial neoplasia or cervical cancer. Study Details In the trial, 194 evaluable patients who reported current...

breast cancer
genomics/genetics

Obesity May Contribute to Breast Cancer Risk in High-Risk Patients With BRCA Mutations

Obesity may spur DNA damage in the breast tissue of patients who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in patients who are already at a higher risk of the disease, according to a new study published by Bhardwaj et al in Science Translational Medicine....

gastroesophageal cancer

Lower-Income Patients With Early-Stage Esophageal Adenocarcinoma May Face Disparities in Cancer Care and Higher Mortality Rates

Patients with early-stage esophageal adenocarcinoma from lower-income households may be significantly less likely to receive a potentially life-saving treatment and may be more likely to die from the disease, according to a new study published by Geng et al in Clinical Gastroenterology and...

prostate cancer

First-Line Systemic Treatments in Metastatic Castration-Sensitive Prostate Cancer

In a systematic review and meta-analysis reported in JAMA Oncology, Riaz et al found that first-line triplet therapy in metastatic castration-sensitive prostate cancer did not appear to offer an overall survival advantage vs androgen pathway inhibitor doublet therapy. As stated by the...

issues in oncology

FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval

On March 24, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications. The accelerated approval pathway is...

Highlights From the SSO 2023 International Conference on Surgical Cancer Care

On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we’ll share results of the SWOG S1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then,...

issues in oncology
global cancer care

It Is Time to Close the Gap in Cancer Care

Cancer is a leading cause of death in every country worldwide.1 In 2020, almost 10 million people died of cancer, a number that is expected to rise to 16.3 million by 2040.2 In addition, cancer incidence continues to grow, driven by an aging and growing population and changes in the prevalence and...

ASCO Celebrates the Cancer Moonshot on Its Relaunch Anniversary

“Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of ...

Eight Oncology Health Systems Participating in Efforts to Improve Vaccination Rates Among High-Risk Adults

ASCO is working with eight oncology health systems to develop, test, and measure strategies to improve immunization rates as part of an initiative with the Council of Medical Specialty Societies (CMSS) to improve vaccination rates among high-risk adults. Through this project, known as Specialty...

2024 ACA Proposal Aims to Reduce Health-Care Coverage Gaps

ASCO submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2024 Notice of Benefit and Payment Parameters proposed rule. ASCO’s comments support proposals aimed at reducing or eliminating gaps in health-care coverage, and ...

Three Models Testing Ways to Lower Drug Costs Outlined in Health and Human Services Report

On February 14, 2023, the Centers for Medicare & Medicaid Services (CMS) announced that the Secretary of the Department of Health and Human Services (HHS) selected three models aiming to address high prescription drug costs for testing by the Center for Medicare and Medicaid Innovation (CMMI)....

breast cancer
immunotherapy

ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...

breast cancer
immunotherapy

DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer

As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with...

lung cancer
genomics/genetics

Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation

As reported in The Lancet by ­Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...

multiple myeloma
immunotherapy

Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma

As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...

lymphoma

Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On January 27, 2023, pirtobrutinib was granted accelerated approval for treatment of relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.1 Pirtobrutinib is a noncovalent inhibitor of BTK. Supporting Efficacy...

colorectal cancer

10 Facts About Colorectal Cancer From the Colorectal Cancer Alliance

March is widely recognized worldwide as Colorectal Cancer Awareness month. Several advocacy groups and professional organizations recognize Colorectal Cancer Awareness month by promoting screening for eligible individuals and working to increase awareness. Here, the Colorectal Cancer Alliance, an...

colorectal cancer

Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber

Colorectal cancer is the third most common cancer among men and women of all ages in the United States and is on track to be the leading cause of cancer death in adults younger than 50 by 2030. The alarming rise of colorectal cancer in people younger than age 50 prompted the U.S. Preventive...

gynecologic cancers
immunotherapy

Regular Approval for Dostarlimab-gxly in dMMR Recurrent or Advanced Endometrial Cancer

On February 9, 2023, dostarlimab-gxly was granted regular approval for adults with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a U.S. Food and Drug Administration–approved test, whose disease has progressed on or following a prior platinum-containing...

issues in oncology

Association of Baseline and Subsequent Cardiovascular Health Metrics to Risk for Incident Cancers

In an analysis from the French GAZEL study reported in JACC: CardioOncology, Thomas Van Sloten, MD, PhD, of the Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, and colleagues found that better cardiovascular health (CVH) scores at baseline and improvement in ...

issues in oncology

Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among U.S. Patients With Cancer

In an analysis reported in JACC: CardioOncology, Cenjing Zhu, MPhil, of the Department of Chronic Disease Epidemiology, Yale University, and colleagues found that Black patients with cancer in the United States were at increased risk of all-cause mortality and cardiovascular (CVD) mortality...

prostate cancer
genomics/genetics

Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...

bladder cancer
immunotherapy

Expert Point of View: Xin Gao, MD

Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2. “These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This...

bladder cancer
immunotherapy

Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer

Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...

Advertisement

Advertisement



Advertisement